15958-69-7Relevant articles and documents
Method for catalytically synthesizing N-aryl/alkyl anthraquinone and derivatives thereof by using carbene metal ligand
-
Paragraph 0020, (2020/07/13)
The invention discloses a method for catalytically synthesizing N-aryl/alkyl anthraquinone and derivatives thereof by using a carbene metal ligand. The method for catalytically synthesizing the N-aryl/alkyl anthraquinone and the derivatives thereof by using the carbene metal ligand provided by the invention comprises the following steps: with the carbene metal ligand and alkali as catalysts and anthraquinone compounds and primary amine compounds as raw materials, allowing the anthraquinone compounds and the primary amine compounds to react in an organic solvent at 100-150 DEG C for 2-12 hours;cooling a reaction liquid after the reaction is finished, and carrying out rotary evaporation so as to remove the solvent; purifying a crude product through a silicon dioxide column, and carrying outeluting with petroleum ether/dichloromethane so as to obtain pure N-aryl/alkyl anthraquinone and derivatives thereof. According to the invention, the selectivity of a tetra-substituted target productis improved and is 90% or above; byproducts are few, and the separation cost of a product is reduced; the reaction is carried out in the organic solvent without water and oxyge;, simple reaction conditions and easy operation are achieved; and industrial production is facilitated.
Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives
-
Page 9, (2008/06/13)
This invention relates to novel anthraquinone compounds useful in the treatment of allergic, inflammatory conditions, antioxidant, tumor condition, stem cell application, tissue engineering, applied in treating age-associate tissue degeneration, reverse organ failure in chronic high-turnover disease and therapeutic compositions containing such compounds. The compounds of the present invention are 1,4-, 1,5- and 1,8-difunctionalized anthraquinones or analogs thereof. According to the practice of the invention, there are provided bis-symmetrical substituted anthraquinone compounds according to formula I: wherein R1, R2, R3 and R4 present a straight, aminoalkylamino side chains or branched chain alkyl group having 1 to 6 carbons which may be substituted with one or more groups of R5, or R1, R2, R3 and R4 present phenyl or benzyl which may be substituted with one or two groups of R6; wherein R5 is selected from the group consisting of halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, and —OCH2CH2CH3; and wherein R6 is selected from the group consisting of a straight or branched chain alkyl group having 1 to 4 carbons, halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, —OCH2CH2CH3, —CH2Br, —CH2Cl, —CH2OH, —C(CH3)3, —(CH2)20H, —(CH2)3OH, —(CH2)4OH, —CH2NH2, —(CH2)2NH2, —(CH2)3NH2, —(CH2)4NH2, —(CH2)5NH2, —CH2N(CH3)2, —(CH2)2N(CH3)2, —(CH2)2NH(CH2)2OH, —(CH2)3NH(CH2)2OH, —(CH2)2NHCH2OH, —(CH2)3NHCH2OH, —CH2CH(CH3)2, —CHCl2, —CH(CH3)Cl, —(CH2)2Cl, —(CH2)3Cl, —(CH2)3Br, —(CH2)4Br, and —(CH2)4Cl. Chart 1. Activation of hTERT promoter-driven SEAP expression by c-Myc. About 1×107 hTERT-BJ1 cells were transfected with 13.5 μg each of plasmid pSEAP or pPhTERT-SEAP and of plasmid pMT2T or pMT2T-cMyc by electroporation. After 24 h, viable cells were harvested, and reinoculated at a density of 3×105/mL, and the SEAP activity after 24 h at 37 □. The transfection efficiency of each experiment was determined by cotransfection with 1.5 μg of plasmid pCMVβ. The values were determined from three experiments. P0.05 is presented by an asterisk.
